Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kidney Transplant Endpoints Strive For Acceptance At FDA Workshop

Executive Summary

Traditional endpoints are becoming increasingly difficult to use successfully in clinical trials because the standard of care has become highly effective.

Advertisement

Related Content

Chronic Kidney Disease Trials Could Gain New Surrogate Endpoints
Zortress Approval Delay Caused By Novartis Attempts To Avoid Controlled Trial Of Dosing Regimen

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel